276 related articles for article (PubMed ID: 23899532)
1. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
[TBL] [Abstract][Full Text] [Related]
3. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH
Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Bodoky G; Scheulen ME; Rivera F; Jassem J; Carrato A; Moiseyenko V; Vynnychenko I; Prausová J; Van Laethem JL; Cascinu S; Ajani JA
J Gastrointest Cancer; 2015 Jun; 46(2):109-17. PubMed ID: 25707610
[TBL] [Abstract][Full Text] [Related]
5. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
[TBL] [Abstract][Full Text] [Related]
6. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
[TBL] [Abstract][Full Text] [Related]
7. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
[TBL] [Abstract][Full Text] [Related]
12. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Dank M; Zaluski J; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Cisar L; Wang K; Bugat R
Ann Oncol; 2008 Aug; 19(8):1450-1457. PubMed ID: 18558665
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Hamada C; Yamada Y; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hyodo I
Int J Clin Oncol; 2016 Aug; 21(4):668-675. PubMed ID: 26733020
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
[TBL] [Abstract][Full Text] [Related]
18. Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer.
Terazawa T; Iwasa S; Takashima A; Nishitani H; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2111-6. PubMed ID: 24129809
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
